<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13245">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00414050</url>
  </required_header>
  <id_info>
    <org_study_id>2006_053</org_study_id>
    <secondary_id>V232-057</secondary_id>
    <nct_id>NCT00414050</nct_id>
  </id_info>
  <brief_title>A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants</brief_title>
  <official_title>A Study to Assess the Safety, Tolerability, and Immunogenicity of 2 Antigen Doses of Recombinant Hepatitis B Vaccine Manufactured With a Modified Process Administered to Healthy Infants at 2, 4, and 6 Months of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>Norway: Norwegian Medicines Agency</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was conducted in healthy infants and will provide new immunogenicity and safety
      data for the modified process hepatitis B vaccine. This study was conducted to address the
      following: to evaluate the immunogenicity and safety data of the 5 microgram dose of the
      modified process hepatitis B vaccine compared with a 10 microgram dose of the modified
      process hepatitis B vaccine&quot;, to evaluate another dosing schedule of 2, 4, and 6 months, and
      to provide descriptive immunogenicity data of another marketed vaccine (ENGERIX-B™).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>The Number of Seroresponders to the Modified Process Hepatitis B Vaccine (5µg and 10 µg Dose), RECOMBIVAX-HB™ Hepatitis B Vaccine (Currently Licensed Vaccine), and ENGERIX-B®</measure>
    <time_frame>7 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Induced (Effected) Geometric Mean Titer for Modified Process Vaccine (5 µg and 10 µg), RECOMBIVAX Hepatitis B (Currently Licensed Vaccine), and ENGERIX-B®</measure>
    <time_frame>7 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1718</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modified Process Hepatitis B vaccine, 5 micrograms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RECOMBIVAX HB™</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modified process hepatitis B vaccine 10 micrograms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ENGERIX-B</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Modified Process Hepatitis B Vaccine (Experimental)</intervention_name>
    <description>Modified Process Hepatitis B Vaccine (Experimental) given IM (Intramuscular) in 3 Injections of 5 ug (micrograms)/0.5 mL each over 4 months (Arm 1). Modified Process Hepatitis B Vaccine (Experimental) given IM (Intramuscular) in 3 Injections of 10 ug (micrograms)/0.5 mL each over 4 months (Arm 3).</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepatitis B Vaccine (Recombinant)</intervention_name>
    <description>RECOMBIVAX HB (currently licensed product) given IM (Intramuscular) in 3 Injections of 5 ug (micrograms)/0.5 mL each over 4 months.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: ENGERIX-B</intervention_name>
    <description>ENGERIX-B given IM (Intramuscular) in 3 Injections of 10 ug (micrograms)/0.5 mL each over 4 months</description>
    <arm_group_label>4</arm_group_label>
    <other_name>ENGERIX-B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject (Participant) is a healthy infant approximately 2 months of age

        Exclusion Criteria:

          -  Birth mother is a known carrier of hepatitis B virus or another known carrier has
             lived in close contact with the subject

          -  Subject's (Participant) birth mother did not receive any prenatal care

          -  Subject (Participant) has previous history of hepatitis B infection

          -  Subject (Participant) has been vaccinated against hepatitis B or birth mother was
             vaccinated within 6 months before birth of subject

          -  Subject (Participant) has had a fever within 72 hours of study start

          -  Subject (Participant) has received any blood-derived product or birth mother received
             blood-derived product within 6 months of birth of subject
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>2 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Finland</country>
    <country>Norway</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <verification_date>May 2009</verification_date>
  <lastchanged_date>May 19, 2009</lastchanged_date>
  <firstreceived_date>December 20, 2006</firstreceived_date>
  <firstreceived_results_date>October 15, 2008</firstreceived_results_date>
  <responsible_party>
    <name_title>Executive Vice President, Clinical and Quantitative Sciences</name_title>
    <organization>Merck &amp; Co., Inc.</organization>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>15-Nov-2006 (First Participant Enrolled in Study) to 24-Oct-2007 (Last Participant had their Last Visit). Last participant completed follow-up: 16-Oct-2007.This study was conducted at 15 sites; 14 in Finland and 1 in Norway.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Modified Process Hepatitis B Vaccine, 5µg (Micrograms)</title>
          <description>Modified Process Hepatitis B Vaccine (Experimental) given IM (Intramuscular) in 3 Injections of 5 ug (micrograms)/0.5 mL each over 4 months</description>
        </group>
        <group group_id="P2">
          <title>RECOMBIVAX™ Hepatitis B Vaccine</title>
          <description>RECOMBIVAX HB (currently licensed product) given IM (Intramuscular) in 3 Injections of 5 ug (micrograms)/0.5 mL each over 4 months</description>
        </group>
        <group group_id="P3">
          <title>Modified Process Hepatitis B Vaccine 10 µg (Micrograms)</title>
          <description>Modified Process Hepatitis B Vaccine (Experimental) given IM (Intramuscular) in 3 Injections of 10 ug (micrograms)/0.5 mL each over 4 months</description>
        </group>
        <group group_id="P4">
          <title>ENGERIX-B</title>
          <description>ENGERIX-B given IM (Intramuscular) in 3 Injections of 10 ug (micrograms)/0.5 mL each over 4 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="431"/>
                <participants group_id="P2" count="427"/>
                <participants group_id="P3" count="429"/>
                <participants group_id="P4" count="431"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Vaccination 1</title>
              <participants_list>
                <participants group_id="P1" count="431"/>
                <participants group_id="P2" count="426"/>
                <participants group_id="P3" count="429"/>
                <participants group_id="P4" count="431"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Vaccination 2</title>
              <participants_list>
                <participants group_id="P1" count="425"/>
                <participants group_id="P2" count="421"/>
                <participants group_id="P3" count="425"/>
                <participants group_id="P4" count="425"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Vaccination 3</title>
              <participants_list>
                <participants group_id="P1" count="424"/>
                <participants group_id="P2" count="419"/>
                <participants group_id="P3" count="425"/>
                <participants group_id="P4" count="424"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="422"/>
                <participants group_id="P2" count="419"/>
                <participants group_id="P3" count="423"/>
                <participants group_id="P4" count="423"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject discontinued for other reason</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Moved</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Modified Process Hepatitis B Vaccine, 5µg (Micrograms)</title>
          <description>Modified Process Hepatitis B Vaccine (Experimental) given IM (Intramuscular) in 3 Injections of 5 ug (micrograms)/0.5 mL each over 4 months</description>
        </group>
        <group group_id="B2">
          <title>RECOMBIVAX™ Hepatitis B Vaccine</title>
          <description>RECOMBIVAX HB (currently licensed product) given IM (Intramuscular) in 3 Injections of 5 ug (micrograms)/0.5 mL each over 4 months</description>
        </group>
        <group group_id="B3">
          <title>Modified Process Hepatitis B Vaccine 10 µg (Micrograms)</title>
          <description>Modified Process Hepatitis B Vaccine (Experimental) given IM (Intramuscular) in 3 Injections of 10 ug (micrograms)/0.5 mL each over 4 months</description>
        </group>
        <group group_id="B4">
          <title>ENGERIX-B</title>
          <description>ENGERIX-B given IM (Intramuscular) in 3 Injections of 10 ug (micrograms)/0.5 mL each over 4 months</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="431"/>
                <measurement group_id="B2" value="427"/>
                <measurement group_id="B3" value="429"/>
                <measurement group_id="B4" value="431"/>
                <measurement group_id="B5" value="1718"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="63.2" spread="10.18"/>
                <measurement group_id="B2" value="62.9" spread="10.15"/>
                <measurement group_id="B3" value="63.3" spread="9.83"/>
                <measurement group_id="B4" value="62.8" spread="9.81"/>
                <measurement group_id="B5" value="63.1" spread="9.99"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="190"/>
                <measurement group_id="B2" value="217"/>
                <measurement group_id="B3" value="208"/>
                <measurement group_id="B4" value="201"/>
                <measurement group_id="B5" value="816"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="241"/>
                <measurement group_id="B2" value="210"/>
                <measurement group_id="B3" value="221"/>
                <measurement group_id="B4" value="230"/>
                <measurement group_id="B5" value="902"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Seroresponders to the Modified Process Hepatitis B Vaccine (5µg and 10 µg Dose), RECOMBIVAX-HB™ Hepatitis B Vaccine (Currently Licensed Vaccine), and ENGERIX-B®</title>
        <description>The number of participants as measured by Seroresponse. Seroresponse was defined as anti-hepatitis B surface antibodies greater than or equal to 10mIU/mL.</description>
        <time_frame>7 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Per-protocol Population is defined as the participants able to complete the study as defined by the protocol. Fewer participants were analyzed than planned. A total of 1609 participants were included in the per protocol analysis. A total of 1687 participants completed the three doses of vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Modified Process Hepatitis B Vaccine, 5µg (Micrograms)</title>
            <description>Modified Process Hepatitis B Vaccine (Experimental) given IM (Intramuscular) in 3 Injections of 5 ug (micrograms)/0.5 mL each over 4 months</description>
          </group>
          <group group_id="O2">
            <title>RECOMBIVAX™ Hepatitis B Vaccine</title>
            <description>RECOMBIVAX HB (currently licensed product) given IM (Intramuscular) in 3 Injections of 5 ug (micrograms)/0.5 mL each over 4 months</description>
          </group>
          <group group_id="O3">
            <title>Modified Process Hepatitis B Vaccine 10 µg (Micrograms)</title>
            <description>Modified Process Hepatitis B Vaccine (Experimental) given IM (Intramuscular) in 3 Injections of 10 ug (micrograms)/0.5 mL each over 4 months</description>
          </group>
          <group group_id="O4">
            <title>ENGERIX-B</title>
            <description>ENGERIX-B given IM (Intramuscular) in 3 Injections of 10 ug (micrograms)/0.5 mL each over 4 months</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="405"/>
                  <measurement group_id="O2" value="406"/>
                  <measurement group_id="O3" value="398"/>
                  <measurement group_id="O4" value="400"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Number of Seroresponders to the Modified Process Hepatitis B Vaccine (5µg and 10 µg Dose), RECOMBIVAX-HB™ Hepatitis B Vaccine (Currently Licensed Vaccine), and ENGERIX-B®</title>
            <description>The number of participants as measured by Seroresponse. Seroresponse was defined as anti-hepatitis B surface antibodies greater than or equal to 10mIU/mL.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="402"/>
                  <measurement group_id="O2" value="400"/>
                  <measurement group_id="O3" value="398"/>
                  <measurement group_id="O4" value="398"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Assess whether seroprotection rate in the Modified Hepatitis B Process Vaccine 5mcg group is acceptable, as defined by lower bound of 95% CI exceeding 90%. Per-protocol population.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Percent of Seroresponders</param_type>
            <param_value>99.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>98.3</ci_lower_limit>
            <ci_upper_limit>100.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Assess whether seroprotection rate in the RECOMBIVAX HB™ group is acceptable, as defined by lower bound of 95 percent CI exceeding 90 percent. Per-protocol population.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Percent of Seroresponders</param_type>
            <param_value>98.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>97.2</ci_lower_limit>
            <ci_upper_limit>99.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Induced (Effected) Geometric Mean Titer for Modified Process Vaccine (5 µg and 10 µg), RECOMBIVAX Hepatitis B (Currently Licensed Vaccine), and ENGERIX-B®</title>
        <description>Geometric Mean Titer - Antibody titer is a laboratory test that measures the presence and amount of antibodies in blood.</description>
        <time_frame>7 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per protocol. Fewer participants were analyzed than planned as noted in the previous text and table.</population>
        <group_list>
          <group group_id="O1">
            <title>Modified Process Hepatitis B Vaccine, 5µg (Micrograms)</title>
            <description>Modified Process Hepatitis B Vaccine (Experimental) given IM (Intramuscular) in 3 Injections of 5 ug (micrograms)/0.5 mL each over 4 months</description>
          </group>
          <group group_id="O2">
            <title>RECOMBIVAX™ Hepatitis B Vaccine</title>
            <description>RECOMBIVAX HB (currently licensed product) given IM (Intramuscular) in 3 Injections of 5 ug (micrograms)/0.5 mL each over 4 months</description>
          </group>
          <group group_id="O3">
            <title>Modified Process Hepatitis B Vaccine 10 µg (Micrograms)</title>
            <description>Modified Process Hepatitis B Vaccine (Experimental) given IM (Intramuscular) in 3 Injections of 10 ug (micrograms)/0.5 mL each over 4 months</description>
          </group>
          <group group_id="O4">
            <title>ENGERIX-B</title>
            <description>ENGERIX-B given IM (Intramuscular) in 3 Injections of 10 ug (micrograms)/0.5 mL each over 4 months</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="405"/>
                  <measurement group_id="O2" value="406"/>
                  <measurement group_id="O3" value="398"/>
                  <measurement group_id="O4" value="400"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Induced (Effected) Geometric Mean Titer for Modified Process Vaccine (5 µg and 10 µg), RECOMBIVAX Hepatitis B (Currently Licensed Vaccine), and ENGERIX-B®</title>
            <description>Geometric Mean Titer - Antibody titer is a laboratory test that measures the presence and amount of antibodies in blood.</description>
            <units>mIU/mL</units>
            <param>Geometric Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="748.2" lower_limit="672.0" upper_limit="833.1"/>
                  <measurement group_id="O2" value="376.8" lower_limit="331.4" upper_limit="428.5"/>
                  <measurement group_id="O3" value="981.5" lower_limit="891.0" upper_limit="1081.2"/>
                  <measurement group_id="O4" value="556.6" lower_limit="491.8" upper_limit="629.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison of Induced (effected) Geometric Mean Titer for the Modified Hepatitis B Process Vaccine and RECOMBIVAX Hepatitis B vaccine.</groups_desc>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Modified Process Hepatitis B vaccine-5µg (micrograms) declared non-inferior to RECOMBIVAX HB™ if the lower bound of the 95% Confidence Interval for the ratio of Geometric Mean Titers (Modified Process Vaccine 5 micrograms/RECOMBIVAX HB™) was &gt;= 0.67. The study had 98 percent power for this test, based on an assumption of true equality.</non_inferiority_desc>
            <param_type>Ratio of geometric means.</param_type>
            <param_value>1.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.69</ci_lower_limit>
            <ci_upper_limit>2.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Modified Process Hepatitis B Vaccine, 5µg (Micrograms)</title>
          <description>Modified Process Hepatitis B Vaccine (Experimental) given IM (Intramuscular) in 3 Injections of 5 ug (micrograms)/0.5 mL each over 4 months</description>
        </group>
        <group group_id="E2">
          <title>RECOMBIVAX™ Hepatitis B Vaccine</title>
          <description>RECOMBIVAX HB (currently licensed product) given IM (Intramuscular) in 3 Injections of 5 ug (micrograms)/0.5 mL each over 4 months</description>
        </group>
        <group group_id="E3">
          <title>Modified Process Hepatitis B Vaccine 10 µg (Micrograms)</title>
          <description>Modified Process Hepatitis B Vaccine (Experimental) given IM (Intramuscular) in 3 Injections of 10 ug (micrograms)/0.5 mL each over 4 months</description>
        </group>
        <group group_id="E4">
          <title>ENGERIX-B</title>
          <description>ENGERIX-B given IM (Intramuscular) in 3 Injections of 10 ug (micrograms)/0.5 mL each over 4 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1"/>
                <counts group_id="E2"/>
                <counts group_id="E3"/>
                <counts group_id="E4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1"/>
                <counts group_id="E2"/>
                <counts group_id="E3"/>
                <counts group_id="E4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Clinical and Quantitative Sciences</name_or_title>
      <organization>Merck &amp; Co., Inc.</organization>
      <phone>1 800 672 6372</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
